Marshall Wace, LLP Galera Therapeutics, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.5 - $3.42 $339,632 - $464,617	135,853 Added 74.37%	318,522 $993,000
Q1 2023 May 15, 2023	BUY	$1.48 - $2.68 $270,350 - $489,552	182,669 New	182,669 $467,000
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.39 $22,324 - $43,029	-18,004 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.01 - $4.19 $759 - $1,583	-378 Reduced 2.06%	18,004 $43,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $8.28 $82,128 - $535,451	-64,668 Reduced 77.87%	18,382 $84,000

Q3 2021 Nov 15, 2021	SELL	$7.04 - $10.49 $235,544 - $350,974	-33,458 Reduced 28.72%	83,050 $673,000
Q2 2021 Aug 13, 2021	BUY	$6.08 - $10.44 $379,355 - $651,393	62,394 Added 115.3%	116,508 $1.15 Million
Q1 2021 May 17, 2021	BUY	$8.35 - $12.39 $451,851 - $670,472	54,114 New	54,114 $478,000

10.7M

10.3K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $3.76M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.